- Agios Pharmaceuticals (AGIO -4.4%) and Celgene (CELG -2.2%) extend the exclusivity period tied to a strategic cancer metabolism collaboration agreement (originally struck in 2010) by a year.
- Terms call for CELG to retain its exclusive option on any drug candidates that come out of the AGIO cancer metabolism pipeline until April of 2015.
- CELG is making an upfront payment of $20M to AGIO. (PR)
Celgene, Agios extend cancer collaboration
Dec 11 2013, 14:12 ET